Gras-Le Guen C, Debillon T, Toquet C, Jarry A, Winer N, Jacqueline C, Kergueris M F, Bingen E, Roze J C, Potel G, Bugnon D
Laboratoire d'Antibiologie Clinique et Expérimentale, Faculté de Médecine de Nantes, Centre Hospitalier Universitaire de Nantes, Nantes, France.
Antimicrob Agents Chemother. 2003 Jul;47(7):2125-30. doi: 10.1128/AAC.47.7.2125-2130.2003.
The effect of optimized maternal therapy by bactericidal agents was evaluated in a reproducible rabbit model of Escherichia coli maternofetal infection simulating human pharmacokinetics. Intravenous antibiotic therapy was begun in the pregnant rabbit 12 h after bacterial intrauterine inoculation, using a computer-controlled pump to simulate human pharmacokinetics of ceftriaxone (1 g/day) associated or not with gentamicin (3 mg/kg of body weight/day). Data were compared for fetal survival, quantitative blood cultures, fetal histology in treated versus untreated groups, and maternal and fetal antibiotic concentrations in plasma in treated animals. Antibiotic therapy led to dramatic improvement in maternal outcome (100% survival versus 100% death in the untreated group in association with maternal septicemia). Fetal survival also improved, with the two-drug combination providing a more potent effect. After 3 days of treatment, 32% of fetuses survived with one-drug therapy and 62% with two-drug therapy (Yates corrected chi(2), P < 0.05). In untreated animals, bacterial counts in blood cultures increased rapidly during the first 24 h up to 8.1 +/- 0.5 log CFU/ml, but remained relatively constant at all times with antibiotic treatment: 4.5 +/- 0.7 log CFU/ml at the start of treatment and 6.2 +/- 0.4 and 5.2 +/- 0.9 log CFU/ml after 72 h for one- and two-drug therapy, respectively (data are means +/- standard deviations). The failure of animals to be cured after 3 days of treatment was not due to an inadequate concentration of ceftriaxone, as the residual level in fetal serum at sacrifice was more than 1000 times the MIC of the microbe. Unexpectedly, inflammation in fetal lung decreased in the treated group after as little as 24 h of antibiotic therapy, despite persistent bacteremia. Although maternal outcome improved and drug concentrations were above the MIC, the treatment did not achieve sterilization of fetuses in utero for this rabbit E. coli maternofetal infection. However, fetal survival showed some improvement, and the histologic features of lung inflammation were reduced.
在一种可重复的兔大肠杆菌母婴感染模型中,模拟人体药代动力学,评估了杀菌剂优化母体治疗的效果。在细菌宫内接种后12小时,对怀孕兔子开始静脉抗生素治疗,使用计算机控制泵模拟头孢曲松(1克/天)联合或不联合庆大霉素(3毫克/千克体重/天)的人体药代动力学。比较了治疗组和未治疗组的胎儿存活率、定量血培养、胎儿组织学,以及治疗动物血浆中母体和胎儿的抗生素浓度。抗生素治疗使母体结局显著改善(100%存活,而未治疗组因母体败血症100%死亡)。胎儿存活率也有所提高,两药联合效果更强。治疗3天后,单药治疗的胎儿存活率为32%,两药治疗为62%(Yates校正卡方检验,P<0.05)。在未治疗的动物中,血培养中的细菌计数在最初24小时内迅速增加,最高达到8.1±0.5 log CFU/ml,但在抗生素治疗期间一直保持相对稳定:治疗开始时为4.5±0.7 log CFU/ml,单药和两药治疗72小时后分别为6.2±0.4和5.2±0.9 log CFU/ml(数据为平均值±标准差)。治疗3天后动物未治愈并非由于头孢曲松浓度不足,因为处死时胎儿血清中的残留水平比微生物的最低抑菌浓度高1000倍以上。出乎意料的是,尽管持续存在菌血症,但抗生素治疗仅24小时后,治疗组胎儿肺中的炎症就有所减轻。尽管母体结局有所改善且药物浓度高于最低抑菌浓度,但对于这种兔大肠杆菌母婴感染,治疗并未实现子宫内胎儿的杀菌。然而,胎儿存活率有所提高,肺部炎症的组织学特征有所减轻。